Literature DB >> 9417046

Heparan sulfate undergoes specific structural changes during the progression from human colon adenoma to carcinoma in vitro.

G C Jayson1, M Lyon, C Paraskeva, J E Turnbull, J A Deakin, J T Gallagher.   

Abstract

We report a detailed analysis of heparan sulfate (HS) structure using a model of human colon carcinogenesis. Metabolically radiolabeled HS was isolated from adenoma and carcinoma cells. The chain length of HS was the same in both cell populations (Mr 20,000; 45-50 disaccharides), and the chains contained on average of two sulfated domains (S domains), identified by heparinase I scission. This enzyme produced fragments of approximate size 7 kDa, suggesting that the S domains were evenly spaced in the intact HS chain. The degree of polymer sulfation and the patterns of sulfation were strikingly different between the two HS species. When compared with adenoma HS, the iduronic acid 2-O-sulfate content of the carcinoma-derived material was reduced by 33%, and the overall level of N-sulfation was reduced by 20%. However, the level of 6-O-sulfation was increased by 24%, and this was almost entirely attributable to an enhanced level of N-sulfated glucosamine 6-O-sulfate, a species whose data implied was mainly located in the mixed sequences of alternating N-sulfated and N-acetylated disaccharides. The results indicate that in the transition to malignancy in human colon adenoma cells, the overall molecular organization of HS is preserved, but there are distinct modifications in both the S domains and their flanking mixed domains that may contribute to the aberrant behavior of the cancer cell.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9417046     DOI: 10.1074/jbc.273.1.51

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

1.  Screening for anticoagulant heparan sulfate octasaccharides and fine structure characterization using tandem mass spectrometry.

Authors:  Hicham Naimy; Nancy Leymarie; Joseph Zaia
Journal:  Biochemistry       Date:  2010-05-04       Impact factor: 3.162

2.  Method development and analysis of free HS and HS in proteoglycans from pre- and postmenopausal women: evidence for biosynthetic pathway changes in sulfotransferase and sulfatase enzymes.

Authors:  Wei Wei; Rebecca L Miller; Julie A Leary
Journal:  Anal Chem       Date:  2013-05-28       Impact factor: 6.986

3.  Structure Based Substrate Specificity Analysis of Heparan Sulfate 6-O-Sulfotransferases.

Authors:  Yongmei Xu; Andrea F Moon; Shuqin Xu; Juno M Krahn; Jian Liu; Lars C Pedersen
Journal:  ACS Chem Biol       Date:  2016-11-22       Impact factor: 5.100

Review 4.  Role of heparan sulfate in ocular diseases.

Authors:  Paul J Park; Deepak Shukla
Journal:  Exp Eye Res       Date:  2013-02-11       Impact factor: 3.467

5.  Purification and characterization of heparan sulphate proteoglycan from bovine brain.

Authors:  Y Park; G Yu; N S Gunay; R J Linhardt
Journal:  Biochem J       Date:  1999-12-15       Impact factor: 3.857

6.  Antibody GD3G7 selected against embryonic glycosaminoglycans defines chondroitin sulfate-E domains highly up-regulated in ovarian cancer and involved in vascular endothelial growth factor binding.

Authors:  Gerdy B ten Dam; Els M A van de Westerlo; Anurag Purushothaman; Radu V Stan; Johan Bulten; Fred C G J Sweep; Leon F Massuger; Kazuyuki Sugahara; Toin H van Kuppevelt
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

Review 7.  Syndecans in cartilage breakdown and synovial inflammation.

Authors:  Thomas Pap; Jessica Bertrand
Journal:  Nat Rev Rheumatol       Date:  2012-10-23       Impact factor: 20.543

Review 8.  Syndecan-1: a dynamic regulator of the myeloma microenvironment.

Authors:  Ralph D Sanderson; Yang Yang
Journal:  Clin Exp Metastasis       Date:  2007-11-20       Impact factor: 5.150

9.  Up-regulation of heparan sulfate 6-O-sulfation in idiopathic pulmonary fibrosis.

Authors:  Jingning Lu; Linda Auduong; Eric S White; Xinping Yue
Journal:  Am J Respir Cell Mol Biol       Date:  2014-01       Impact factor: 6.914

10.  The anticancer activity of lytic peptides is inhibited by heparan sulfate on the surface of the tumor cells.

Authors:  Bodil Fadnes; Oystein Rekdal; Lars Uhlin-Hansen
Journal:  BMC Cancer       Date:  2009-06-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.